Intellia Therapeutics (NASDAQ:NTLA) Sets New 12-Month Low After Analyst Downgrade
Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report)’s share price hit a new 52-week low during trading on Tuesday after Truist Financial lowered their price target on the stock from $90.00 to $50.00. Truist Financial currently has a buy rating on the stock. Intellia Therapeutics traded as low as $8.36 and last traded at $8.58, […]
Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report)’s share price hit a new 52-week low during trading on Tuesday after Truist Financial lowered their price target on the stock from $90.00 to $50.00. Truist Financial currently has a buy rating on the stock. Intellia Therapeutics traded as low as $8.36 and last traded at $8.58, […]
